Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (review).

No abstract is available for this paper.

• Publication year

  2014

• Venue

  International Journal of Oncology

• Publication date

  2014-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3892/ijo.2014.2525PMID 24968804
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rapamycin interacts synergistically with idarubicin to induce T-leukemia cell apoptosis in vitro and in a mesenchymal stem cell simulated drug-resistant microenvironment via Akt/mammalian target of rapamycin and extracellular signal-related kinase signaling pathways

  2014cited by this paper
• Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis

  2014cited by this paper
• Loss of mTOR complex 1 induces developmental blockage in early T-lymphopoiesis and eradicates T-cell acute lymphoblastic leukemia cells

  2014cited by this paper
• Resistance to mTOR Kinase Inhibitors in Lymphoma Cells Lacking 4EBP1

  2014cited by this paper
• Evolution of the cancer stem cell model.

  2014cited by this paper
• Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors

  2014cited by this paper
• Strategies for the management of adverse events associated with mTOR inhibitors.

  2014cited by this paper
• mTOR/PRAS40 interaction

  2013cited by this paper
• Notch1 Receptor Regulates AKT Protein Activation Loop (Thr308) Dephosphorylation through Modulation of the PP2A Phosphatase in Phosphatase and Tensin Homolog (PTEN)-null T-cell Acute Lymphoblastic Leukemia Cells*

  2013cited by this paper
• Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia

  2013cited by this paper
• Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer.

  2013cited by this paper
• Chemotherapy induced DNA damage response

  2013cited by this paper
• Glucocorticoid sensitivity of T-cell lymphoblastic leukemia/lymphoma is associated with glucocorticoid receptor-mediated inhibition of Notch1 expression

  2013cited by this paper
• Novel TAL1 targets beyond protein-coding genes: identification of TAL1-regulated microRNAs in T-cell acute lymphoblastic leukemia

  2013cited by this paper
• The molecular profile of adult T‐cell acute lymphoblastic leukemia: Mutations in RUNX1 and DNMT3A are associated with poor prognosis in T‐ALL

  2013cited by this paper
• Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial

  2013cited by this paper
• FBXW7 regulates glucocorticoid response in T-cell acute lymphoblastic leukaemia by targeting the glucocorticoid receptor for degradation

  2013cited by this paper
• Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia

  2013cited by this paper
• Acute lymphoblastic leukaemia.

  2013cited by this paper
• Mammalian Target of Rapamycin (mTOR) Activity Dependent Phospho-Protein Expression in Childhood Acute Lymphoblastic Leukemia (ALL)

  2013cited by this paper
• Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study.

  2013cited by this paper
• Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas.

  2013cited by this paper
• The NOTCH signaling pathway: role in the pathogenesis of T-cell acute lymphoblastic leukemia and implication for therapy

  2013cited by this paper
• mTORC1 Phosphorylation Sites Encode Their Sensitivity to Starvation and Rapamycin

  2013cited by this paper
• Receptor kinase profiles identify a rationale for multitarget kinase inhibition in immature T-ALL

  2013cited by this paper
• A Phase I/II Study Of Hyper-CVAD Plus Everolimus In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

  2013cited by this paper
• NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia

  2013cited by this paper
• Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment

  2013cited by this paper
• A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse

  2013cited by this paper
• The role of HOX genes in normal hematopoiesis and acute leukemia

  2013cited by this paper
• Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression.

  2012cited by this paper
• The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia

  2012cited by this paper
• Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family.

  2012cited by this paper
• An oncogenic role of miR-142-3p in human T-cell acute lymphoblastic leukemia (T-ALL) by targeting glucocorticoid receptor-α and cAMP/PKA pathways

  2012cited by this paper
• Dual PI3K/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1α expression by blocking protein translation and increases cell death under hypoxia

  2012cited by this paper
• NOTCH1 Signaling Promotes Human T-Cell Acute Lymphoblastic Leukemia Initiating Cell Regeneration in Supportive Niches

  2012cited by this paper
• MicroRNAs in acute leukemia: from biological players to clinical contributors

  2012cited by this paper
• The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells.

  2012cited by this paper
• Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels

  2012cited by this paper
• PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response

  2012cited by this paper
• Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.

  2012cited by this paper
• Molecular genetics of B-precursor acute lymphoblastic leukemia.

  2012cited by this paper
• Notch signaling expands a pre-malignant pool of T-cell acute lymphoblastic leukemia clones without affecting leukemia-propagating cell frequency

  2012cited by this paper
• An overview of the mTOR pathway as a target in cancer therapy

  2012cited by this paper
• mTOR signaling in growth control and disease.

  2012cited by this paper
• Cytogenetic and Molecular Predictors of Outcome in Acute Lymphocytic Leukemia: Recent Developments

  2012cited by this paper
• The molecular basis of T cell acute lymphoblastic leukemia.

  2012cited by this paper
• The genomics revolution: relevance in healthcare today and tomorrow

  2012cited by this paper
• Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.

  2012cited by this paper
• Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia

  2012cited by this paper
• Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies.

  2012cited by this paper
• Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment

  2012cited by this paper
• Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response

  2012cited by this paper
• The cancer stem cell: premises, promises and challenges

  2011cited by this paper
• Rapamycin passes the torch: a new generation of mTOR inhibitors

  2011cited by this paper
• Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers.

  2011cited by this paper
• Leukemia stem cells

  2011cited by this paper
• Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia

  2011cited by this paper
• Intracellular reactive oxygen species are essential for PI3K/Akt/mTOR-dependent IL-7-mediated viability of T-cell acute lymphoblastic leukemia cells

  2011cited by this paper
• ATP-competitive inhibitors of mTOR: an update.

  2011cited by this paper
• Dual mTORC2/mTORC1 Targeting Results in Potent Suppressive Effects on Acute Myeloid Leukemia (AML) Progenitors

  2011cited by this paper
• Transcriptional control of cellular metabolism by mTOR signaling.

  2011cited by this paper
• Suppression of leukemia development caused by PTEN loss

  2011cited by this paper
• Genomic profiling of B-progenitor acute lymphoblastic leukemia.

  2011cited by this paper
• Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway

  2011cited by this paper
• Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia

  2011cited by this paper
• Targeting glycolysis in leukemia: a novel inhibitor 3-BrOP in combination with rapamycin.

  2011cited by this paper
• Expression of CD34 and CD7 on human T-cell acute lymphoblastic leukemia discriminates functionally heterogeneous cell populations

  2011cited by this paper
• Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.

  2011cited by this paper
• mTOR complex 2 signaling and functions

  2011cited by this paper
• High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling

  2011cited by this paper
• Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia

  2011cited by this paper
• Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy

  2011cited by this paper
• Notch in T-ALL: new players in a complex disease.

  2011cited by this paper
• Leukemia-initiating cells in human T-lymphoblastic leukemia exhibit glucocorticoid resistance.

  2010cited by this paper
• Phosphoinositide signalling in cancer: beyond PI3K and PTEN

  2010cited by this paper
• The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL–BFM 2000 protocol can be separated from FBXW7 loss of function

  2010cited by this paper
• Rictor Phosphorylation on the Thr-1135 Site Does Not Require Mammalian Target of Rapamycin Complex 2

  2010cited by this paper
• Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia

  2010cited by this paper
• Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

  2010cited by this paper
• Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia

  2010cited by this paper
• A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.

  2010cited by this paper
• Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.

  2010cited by this paper
• Role of Pten in leukemia stem cells

  2010cited by this paper
• Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment.

  2010cited by this paper
• The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma

  2010cited by this paper
• The role of the Atg1/ULK1 complex in autophagy regulation.

  2010cited by this paper
• mTOR: from growth signal integration to cancer, diabetes and ageing

  2010cited by this paper
• Updates of mTOR inhibitors.

  2010cited by this paper
• Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways

  2010cited by this paper
• Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells.

  2010cited by this paper
• Akt-dependent and -independent mechanisms of mTOR regulation in cancer.

  2009cited by this paper
• PIM1 Protein Kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells

  2009cited by this paper
• Clinical and cytogenetic features of a population‐based consecutive series of 285 pediatric T‐cell acute lymphoblastic leukemias: Rare T‐cell receptor gene rearrangements are associated with poor outcome

  2009cited by this paper
• mTOR signaling at a glance

  2009cited by this paper
• Targeting translation in acute myeloid leukemia: A new paradigm for therapy?

  2009cited by this paper
• mTOR and cancer: many loops in one pathway.

  2009cited by this paper
• Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy.

  2009cited by this paper
• Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.

  2009cited by this paper
• Molecular mechanisms of mTOR-mediated translational control

  2009cited by this paper

• Anlotinib exerts an anti-T-cell acute lymphoblastic leukemia effect in vitro and in vivo.

  2023cites this paper
• PTEN/PI3K/Akt pathway alters sensitivity of T-cell acute lymphoblastic leukemia to l-asparaginase

  2022cites this paper
• miRNA-425-5p enhances diffuse large B cell lymphoma growth by targeting PTEN

  2021cites this paper
• SIX6 is a TAL1-regulated transcription factor in T-ALL and associated with inferior outcome

  2020cites this paper
• Recent Advances in Molecular Diagnosis and Prognosis of Childhood B Cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

  2020cites this paper
• Comparison of rapamycin and methylprednisolone for treating inflammatory muscle disease in a murine model of experimental autoimmune myositis

  2020cites this paper
• Targeting Wnt/β‐catenin and PI3K/Akt/mTOR pathways in T‐cell acute lymphoblastic leukemia

  2020cites this paper
• Treatment of keloids through Runx2 siRNA-induced inhibition of the PI3K/AKT signaling pathway

  2020cites this paper
• Targeting mTOR in Acute Lymphoblastic Leukemia

  2019cites this paper
• Overexpression of CD59 inhibits apoptosis of T-acute lymphoblastic leukemia via AKT/Notch1 signaling pathway

  2019cites this paper
• Novel targeted therapeutic agents for the treatment of childhood, adolescent and young adult non‐Hodgkin lymphoma

  2019cites this paper
• Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update

  2018cites this paper
• MNK1 inhibitor CGP57380 overcomes mTOR inhibitor-induced activation of eIF4E: the mechanism of synergic killing of human T-ALL cells

  2018cites this paper
• Therapeutic targeting of CK2 in acute and chronic leukemias

  2017cites this paper
• Characterization of select downstream effectors of oncogenic NOTCH1 in T-cell acute lymphoblastic leukemia

  2016cites this paper
• miR-125b regulates differentiation and metabolic reprogramming of T cell acute lymphoblastic leukemia by directly targeting A20

  2016cites this paper
• Autophagy in acute leukemias: a double-edged sword with important therapeutic implications.

  2015cites this paper
• How I treat T-cell acute lymphoblastic leukemia in adults.

  2015cites this paper
• Lithium Chloride Promotes Apoptosis in Human Leukemia NB4 Cells by Inhibiting Glycogen Synthase Kinase-3 Beta

  2015cites this paper
• Differential profile of PIP4K2A expression in hematological malignancies.

  2015cites this paper